The United States Preventive Services Task Force (USPSTF) has released new recommendations on screening for cervical cancer. These latest recommendations continue the trend of decreasing participant burden by lengthening screening intervals, making the "annual Pap" a historical artifact. Since its introduction 75 years ago, exfoliative cytology commonly known as the Pap test has been the "gold-standard" screening test for cervical cancer.
You are here
In a "proof of concept" study, scientists at Johns Hopkins Medicine say they have successfully delivered nano-size packets of genetic code called microRNAs to treat human brain tumors implanted in mice. The contents of the super-small containers were designed to target cancer stem cells, a kind of cellular "seed" that produces countless progeny and is a relentless barrier to ridding the brain of malignant cells.
Results of their experiments were published online June 21 in Nano Letters.
First-line Treatment With Checkpoint Inhibitors Associated With Improved Overall Survival For Patients With Melanoma Brain Metastases
Bottom Line: Among patients with cutaneous melanoma who had brain metastases (MBM), first-line treatment with a checkpoint inhibitor was associated with a 1.4-fold increase in median overall survival, according to results from a national cohort.
Journal in Which the Study was Published: Cancer Immunology Research, a journal of the American Association for Cancer Research.
Would banning ventilated filters on cigarettes protect public health?
Scientists from multiple institutions, including a group of addiction neuroscience researchers from the Virginia Tech Carilion Research Institute, are gathering evidence under funding from the National Institutes of Health's National Cancer Institute to potentially inform a U.S. Food and Drug Administration (FDA) decision about whether to recommend design changes to filtered cigarettes.
The team of María Domínguez, researcher for the Neuroscience Institute, joint venture of the Miguel Hernández University (UMH) in Elche and the Spanish National Research Council (CSIC), has managed to prove for the first time that an important factor in the development of acute pediatric lymphoblastic leukemia is inflammation. Moreover, researchers have readied a screening system in order to choose the medicines which are already being used to fight inflammatory processes which could be effective against this type of childhood cancer and without side effects.
Imagine a microscopic gold pill that could travel to a specific location in your body and deliver a drug just where it is needed. This is the promise of plasmonic nanovesicles.
These minute capsules can navigate the bloodstream, and, when hit with a quick pulse of laser light, change shape to release their contents. It can then exit the body, leaving only the desired package.
Researchers at Albert Einstein College of Medicine have found that when human papillomavirus (HPV)-16 is detected in peoples' mouths, they are 22 times more likely than those without HPV-16 to develop a type of head and neck cancer. The study was published online today in JAMA Oncology and was led by Ilir Agalliu, M.D., Sc.D., and Robert D. Burk, M.D.
Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced the publication of further results from the Primary ASC-US LSIL Marker Study (PALMS) in this month's issue of Cancer Cytopathology. The PALMS study, which enrolled more than 27,000 women from five European countries, was designed to evaluate the diagnostic performance of the CINtec® PLUS Cytology test in detecting pre-cancerous cervical disease compared to HPV testing and more traditional screening methods like Pap cytology.
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels to proliferate. Their earlier research- which first implicated nerves in fueling prostate cancer- has prompted Montefiore-Einstein to conduct a pilot study testing whether beta blockers (commonly used for treating hypertension) can kill cancer cells in tumors of men diagnosed with prostate cancer.
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) approved the cobas® HPV (Human Papillomavirus) Test for use as a first-line primary screening test for cervical cancer in women 25 and older. The approval follows the March 12 unanimous recommendation from the Microbiology Devices Panel of the FDA's Medical Devices Advisory Committee, making the cobas® HPV Test the first and only HPV test in the United States approved for first-line primary screening.